Literature DB >> 19034426

Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU.

Elisabeth Meyer1, Matthias Lapatschek, Andreas Bechtold, Gerhard Schwarzkopf, Petra Gastmeier, Frank Schwab.   

Abstract

OBJECTIVE: To test whether a reduction of third generation cephalosporin (3GC) use has a sustainable positive impact on the high endemic prevalence of 3GC resistant K. pneumoniae and E. coli.
DESIGN: Segmented regression analysis of interrupted time series was used to analyse antibiotic consumption and resistance data 30 months before and 30 after the intervention.
SETTING: Surgical intensive care unit (ICU) with 16-bed unit in a teaching hospital. INTERVENTION: In July 2004, 3GCs were switched to piperacillin in combination with a beta-lactamase-inhibitor as standard therapy for peritonitis and other intraabdominal infections.
RESULTS: Segmented regression analysis showed that the intervention achieved a significant and sustainable decrease in the use of 3GCs of -110.2 daily defined doses (DDD)/1,000 pd. 3GC use decreased from a level of 178.9 DDD/1,000 pd before to 68.7 DDD/1,000 pd after the intervention. The intervention resulted in a mean estimated reduction in total antibiotic use of 27%. Piperacillin/tazobactam showed a significant increase in level of 64.4 DDD/1,000 pd, and continued to increase by 2.3 DDD/1,000 pd per month after the intervention. The intervention was not associated with a significant change in the resistance densities of 3GC resistant K. pneumoniae and E. coli.
CONCLUSION: Reducing 3GCs does not necessarily impact positively on the resistance situation in the ICU setting. Likewise, replacing piperacillin with beta-lactamase inhibitor might provide a selection pressure on 3GC resistant E. coli and K. pneumoniae. To improve resistance, it might not be sufficient to restrict interventions to a risk area.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034426     DOI: 10.1007/s00134-008-1355-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  24 in total

1.  Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis.

Authors:  Faranak Ansari; Kirsteen Gray; Dilip Nathwani; Gabby Phillips; Simon Ogston; Craig Ramsay; Peter Davey
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

Review 2.  Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing.

Authors:  Craig Ramsay; Erwin Brown; Giles Hartman; Peter Davey
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

3.  Segmented regression analysis of interrupted time series studies in medication use research.

Authors:  A K Wagner; S B Soumerai; F Zhang; D Ross-Degnan
Journal:  J Clin Pharm Ther       Date:  2002-08       Impact factor: 2.512

Review 4.  Potential confounding in evaluating infection-control interventions in hospital settings: changing antibiotic prescription.

Authors:  S Nijssen; M Bootsma; M Bonten
Journal:  Clin Infect Dis       Date:  2006-07-31       Impact factor: 9.079

5.  Restriction of third-generation cephalosporin use decreases infection-related mortality.

Authors:  Bin Du; Dechang Chen; Dawei Liu; Yun Long; Yan Shi; Hao Wang; Xi Rui; Na Cui
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

6.  Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region.

Authors:  Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Sameer Elsayed; Kevin B Laupland
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Antibiotic restriction does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit.

Authors:  P Toltzis; T Yamashita; L Vilt; M Green; A Morrissey; S Spinner-Block; J Blumer
Journal:  Crit Care Med       Date:  1998-11       Impact factor: 7.598

8.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

9.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.

Authors:  Bin Du; Yun Long; Hongzhong Liu; Dechang Chen; Dawei Liu; Yingchun Xu; Xiuli Xie
Journal:  Intensive Care Med       Date:  2002-10-17       Impact factor: 17.440

10.  Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission.

Authors:  Anthony D Harris; Jessina C McGregor; Judith A Johnson; Sandra M Strauss; Anita C Moore; Harold C Standiford; Joan N Hebden; J Glenn Morris
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more
  9 in total

Review 1.  Interventions to improve antibiotic prescribing practices for hospital inpatients.

Authors:  Peter Davey; Charis A Marwick; Claire L Scott; Esmita Charani; Kirsty McNeil; Erwin Brown; Ian M Gould; Craig R Ramsay; Susan Michie
Journal:  Cochrane Database Syst Rev       Date:  2017-02-09

Review 2.  Unraveling the Nature of Antibiotics: Is It a Cure or a New Hurdle to the Patient Treatment?

Authors:  Sai Sreeya Gude; Shravya Venu Gopal; Harshita Marasandra Ramesh; Sravya Vuppalapati; Nikhil Chowdary Peddi; Sai Sravya Gude
Journal:  Cureus       Date:  2022-04-08

3.  Studying Factors Affecting Success of Antimicrobial Resistance Interventions through the Lens of Experience: A Thematic Analysis.

Authors:  Tiscar Graells; Irene A Lambraki; Melanie Cousins; Anaïs Léger; Kate Lillepold; Patrik J G Henriksson; Max Troell; Carolee A Carson; Elizabeth Jane Parmley; Shannon E Majowicz; Didier Wernli; Peter Søgaard Jørgensen
Journal:  Antibiotics (Basel)       Date:  2022-05-10

4.  Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008.

Authors:  Elisabeth Meyer; Frank Schwab; Barbara Schroeren-Boersch; Petra Gastmeier
Journal:  Crit Care       Date:  2010-06-14       Impact factor: 9.097

Review 5.  Year in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-08       Impact factor: 17.440

6.  Impact of restriction of cefepime use on the antimicrobial susceptibility of Gram-negative bacilli related to healthcare-associated infections in an orthopedic hospital.

Authors:  Priscila R Oliveira; Adriana P Paula; Karine Dal-Paz; Cassia S Felix; Flavia Rossi; Jorge S Silva; Ana Lucia M Lima
Journal:  Infect Drug Resist       Date:  2011-08-04       Impact factor: 4.003

7.  Antibiotic consumption and its influence on the resistance in Enterobacteriaceae.

Authors:  Miroslava Htoutou Sedláková; Karel Urbánek; Vladimíra Vojtová; Hana Suchánková; Peter Imwensi; Milan Kolář
Journal:  BMC Res Notes       Date:  2014-07-16

8.  Public health evolutionary biology of antimicrobial resistance: priorities for intervention.

Authors:  Fernando Baquero; Val F Lanza; Rafael Cantón; Teresa M Coque
Journal:  Evol Appl       Date:  2014-12-11       Impact factor: 5.183

9.  Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project.

Authors:  Maria Diletta Pezzani; Fulvia Mazzaferri; Monica Compri; Liliana Galia; Nico T Mutters; Gunnar Kahlmeter; Theoklis E Zaoutis; Mitchell J Schwaber; Jesús Rodríguez-Baño; Stephan Harbarth; Evelina Tacconelli
Journal:  J Antimicrob Chemother       Date:  2020-12-06       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.